Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

医学 内科学 卡铂 人口 安慰剂 临床试验 卵巢癌 临床终点 外科 化疗 肿瘤科 癌症 顺铂 病理 环境卫生 替代医学
作者
Rodney Paul Rocconi,Elizabeth A. Grosen,Sharad A. Ghamande,John K. Chan,Minal A. Barve,Jonathan Oh,Devansu S. Tewari,Peter C Morris,Erin Stevens,Justin N. Bottsford-Miller,Min Tang,Phylicia A. Aaron,Laura Stanbery,Staci Horvath,Gladice Wallraven,Ernest Bognar,Luisa Manning,John J. Nemunaitis,David Shanahan,Brian M. Slomovitz
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (12): 1661-1672 被引量:131
标识
DOI:10.1016/s1470-2045(20)30533-7
摘要

Background Gemogenovatucel-T is an autologous tumour cell vaccine manufactured from harvested tumour tissue, which specifically reduces expression of furin and downstream TGF-β1 and TGF-β2. The aim of this study was to determine the safety and efficacy of gemogenovatucel-T in front-line ovarian cancer maintenance. Methods This randomised, double-blind, placebo-controlled, phase 2b trial involved 25 hospitals in the USA. Women aged 18 years and older with stage III/IV high-grade serous, endometrioid, or clear cell ovarian cancer in clinical complete response after a combination of surgery and five to eight cycles of chemotherapy involving carboplatin and paclitaxel, and an Eastern Cooperative Oncology Group status of 0 or 1 were eligible for inclusion in the study. Patients were randomly assigned (1:1) to gemogenovatucel-T or placebo by an independent third party interactive response system after successful screening using randomly permuted block sizes of two and four and stratified by extent of surgical cytoreduction and neoadjuvant versus adjuvant chemotherapy. Gemogenovatucel-T (1 × 107 cells per injection) or placebo was administered intradermally (one per month) for a minimum of four and up to 12 doses. Patients, investigators, and clinical staff were masked to patient allocation until after statistical analysis. The primary endpoint was recurrence-free survival, analysed in the per-protocol population. All patients who received at least one dose of gemogenovatucel-T were included in the safety analysis. The study is registered with ClinicalTrials.gov, NCT02346747. Findings Between Feb 11, 2015, and March 2, 2017, 310 patients consented to the study at 22 sites. 217 were excluded. 91 patients received gemogenovatucel-T (n=47) or placebo (n=44) and were analysed for safety and efficacy. The median follow-up from first dose of gemogenovatucel-T was 40·0 months (IQR 35·0–44·8) and from first dose of placebo was 39·8 months (35·5–44·6). Recurrence-free survival was 11·5 months (95% CI 7·5–not reached) for patients assigned to gemogenovatucel-T versus 8·4 months (7·9–15·5) for patients assigned to placebo (HR 0·69, 90% CI 0·44–1·07; one-sided p=0·078). Gemogenovatucel-T resulted in no grade 3 or 4 toxic effects. Two patients in the placebo group had five grade 3 toxic events, including arthralgia, bone pain, generalised muscle weakness, syncope, and dyspnea. Seven patients (four in the placebo group and three in the gemogenovatucel-T group) had 11 serious adverse events. No treatment-related deaths were reported in either of the groups. Interpretation Front-line use of gemogenovatucel-T immunotherapy as maintenance was well tolerated but the primary endpoint was not met. Further investigation of gemogenovatucel-T in patients stratified by BRCA mutation status is warranted. Funding Gradalis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
VV发布了新的文献求助10
1秒前
2秒前
Cilinedy完成签到,获得积分10
2秒前
老实路灯发布了新的文献求助10
2秒前
MY发布了新的文献求助10
2秒前
橘子海发布了新的文献求助10
2秒前
ddddd发布了新的文献求助10
3秒前
李爱国的应助被小恶于采纳,获得10
3秒前
高高的哈密瓜完成签到 ,获得积分10
3秒前
3秒前
ssh完成签到,获得积分10
3秒前
锡安111发布了新的文献求助10
4秒前
CC完成签到 ,获得积分10
4秒前
4秒前
123完成签到,获得积分10
5秒前
刘海辉完成签到,获得积分10
5秒前
打打的应助被李子采纳,获得10
5秒前
勤恳的小甜瓜完成签到,获得积分10
5秒前
上林春漫完成签到,获得积分10
5秒前
xueyinging完成签到,获得积分10
6秒前
DW的应助被为什么我不行采纳,获得10
6秒前
6秒前
7秒前
7秒前
7秒前
plm完成签到,获得积分10
8秒前
爱吃辣条完成签到,获得积分10
8秒前
Captain发布了新的文献求助30
9秒前
Fortitude完成签到,获得积分10
9秒前
852的应助被123SDFG采纳,获得10
9秒前
9秒前
Maestro_S的应助被Wangguanbo采纳,获得20
9秒前
青牛发布了新的文献求助10
9秒前
9秒前
caizhizhao完成签到,获得积分10
10秒前
柠檬果完成签到,获得积分10
10秒前
11秒前
jyzx发布了新的文献求助10
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183091
求助须知:如何正确求助?哪些是违规求助? 9572406
关于积分的说明 21825003
捐赠科研通 7779812
什么是DOI,文献DOI怎么找? 3433837
关于科研通互助平台的介绍 2558045
邀请新用户注册赠送积分活动 2480046